Conditions: Alopecia Areata (AA) Alopecia Totalis (AT) Alopecia Universalis (AU)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 30
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Detailed description:
This study is an open-label pilot study. Participants will be treated with oral tofacitinib for a maximum of 5 months. Participants will be evaluated at 3 months after completion of therapy to evaluate for durability of response, late response and/or late adverse effects.

Arms:
arm 1: 5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.

Interventions: intervention 1: Tofacitinib Administration
Intervention descriptions: intervention 1: 5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.

Protocol document: